Celyad to Announce Full Year 2018 Financial Results and Host Conference Call

Celyad to Announce Full Year 2018 Financial Results and Host Conference Call

Celyad’s 2019 R&D Day Highlights shRNA Platform and Pipeline of Next-generation NKG2D-based and Off-the-Shelf Non-gene Edited CAR-T Candidates

Celyad’s 2019 R&D Day Highlights shRNA Platform and Pipeline of Next-generation NKG2D-based and Off-the-Shelf Non-gene Edited CAR-T Candidates

Celyad to Host R&D Day and Webcast on Monday, March 18 in New York City

Celyad to Host R&D Day and Webcast on Monday, March 18 in New York City

Celyad Appoints Anne Moore as Vice President Corporate Strategy

Celyad Appoints Anne Moore as Vice President Corporate Strategy

Celyad Announces February and March 2019 Investor Conference Schedule

Celyad Announces February and March 2019 Investor Conference Schedule

Letter to Shareholders - January 2019

Letter to Shareholders - January 2019

Celyad Outlines Key 2019 Priorities Including the Acceleration of the CYAD-01 Program in r/r AML and MDS

Celyad Outlines Key 2019 Priorities Including the Acceleration of the CYAD-01 Program in r/r AML and MDS

Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting

Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting

Celyad Doses First mCRC Patient in the Phase 1 alloSHRINK Trial Evaluating Non-Gene Edited Allogeneic CAR-T Candidate, CYAD-101

Celyad Doses First mCRC Patient in the Phase 1 alloSHRINK Trial Evaluating Non-Gene Edited Allogeneic CAR-T Candidate, CYAD-101

Celyad Announces Third Quarter 2018 Business Update

Celyad Announces Third Quarter 2018 Business Update

Celyad to Participate at Upcoming Healthcare Conferences

Celyad to Participate at Upcoming Healthcare Conferences

Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting

Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting